Compile Data Set for Download or QSAR
Report error Found 329 Enz. Inhib. hit(s) with all data for entry = 10783
TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440880(US10639284, Compound 3.049 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440884(US10639284, Compound 3.053 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440885(US10639284, Compound 3.054 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440890(US10639284, Compound 3.059 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440891(US10639284, Compound 3.060 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440888(US10639284, Compound 3.057 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440894(US10639284, Compound 3.063 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM36335(US10639284, Compound 1.001 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440893(US10639284, Compound 3.062 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440864(US10639284, Compound 3.033 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440865(US10639284, Compound 3.034 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440870(US10639284, Compound 3.039 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440871(US10639284, Compound 3.040 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440868(US10639284, Compound 3.037 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440869(US10639284, Compound 3.071 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440874(US10639284, Compound 3.043 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440875(US10639284, Compound 3.044 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440852(US10639284, Compound 3.041 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440878(US10639284, Compound 3.047 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440879(US10639284, Compound 3.048 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440914(US10639284, Compound 3.083 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440653(US10639284, Compound 2.005 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440915(US10639284, Compound 3.084 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440654(US10639284, Compound 2.006 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440651(US10639284, Compound 2.003 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440652(US10639284, Compound 3.024 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440658(US10639284, Compound 2.010 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440917(US10639284, Compound 3.086 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440922(US10639284, Compound 3.091 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440926(US10639284, Compound 3.095 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440664(US10639284, Compound 2.015 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440925(US10639284, Compound 3.094 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440636(US10639284, Compound 1.004 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440899(US10639284, Compound 3.068 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440637(US10639284, Compound 1.005 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440635(US10639284, Compound 1.003 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440869(US10639284, Compound 3.071 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440640(US10639284, Compound 1.008 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440903(US10639284, Compound 3.072 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440641(US10639284, Compound 1.009 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440900(US10639284, Compound 3.069 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440901(US10639284, Compound 3.070 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440905(US10639284, Compound 3.074 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440911(US10639284, Compound 3.080 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440650(US10639284, Compound 2.002 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440686(US10639284, Compound 3.114 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440685(US10639284, Compound 2.036 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440950(US10639284, Compound 3.119 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440792(US10639284, Compound 3.120 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440948(US10639284, Compound 3.117 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

Displayed 1 to 50 (of 329 total ) | Next | Last >>
Jump to: